GLIS2 and CCND1 expression levels in breast cancer patients

Basit Öğe Kaydı
dc.authorscopusid57197814420en_US
dc.authorwosidCFW-1256-2022en_US
dc.contributor.authorSadeghi, Minoosh
dc.contributor.authorGholizadeh, Majid
dc.contributor.authorSafataj, Neda
dc.contributor.authorTahmasebivand, Mahsa
dc.contributor.authorMohajeri, Gholamreza
dc.contributor.authorLotfi, Hajie
dc.contributor.authorBostanabad, Saber Yari
dc.contributor.authorSafar, Behnaz
dc.contributor.authorSalehi, Mansoor
dc.date.accessioned2024-01-31T08:19:26Z
dc.date.available2024-01-31T08:19:26Z
dc.date.issued2023en_US
dc.departmentFakülteler, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Farmakoloji Ana Bilim Dalıen_US
dc.description.abstractBreast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis. METHODS: In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes. RESULTS: The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined. CONCLUSION: These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage.en_US
dc.identifier.citationSadeghi, M., Gholizadeh, M., Safataj, N., Tahmasebivand, M., Mohajeri, G., Lotfi, H., Bostanabad, S. Y., Safar, B., & Salehi, M. (2023). GLIS2 and CCND1 expression levels in breast cancer patients. Breast Disease, 42(1), pp. 251–259. https://doi.org/10.3233/BD-220068en_US
dc.identifier.doi10.3233/BD-220068en_US
dc.identifier.endpage259en_US
dc.identifier.issn0888-6008
dc.identifier.issn1558-1551
dc.identifier.issue1en_US
dc.identifier.pmidPMID: 37574724en_US
dc.identifier.scopus2-s2.0-85168059642en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage251en_US
dc.identifier.urihttps://doi.org/10.3233/BD-220068
dc.identifier.urihttps://hdl.handle.net/20.500.13055/646
dc.identifier.volume42en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBostanabad, Saber Yari
dc.language.isoenen_US
dc.publisherIOS Pressen_US
dc.relation.ispartofBreast Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectCCND1en_US
dc.subjectGLIS2en_US
dc.subjectSignaling Pathwayen_US
dc.titleGLIS2 and CCND1 expression levels in breast cancer patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
Ä°sim:
GLIS2 and CCND1 expression levels in breast.pdf
Boyut:
733.8 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

Farmakoloji Ana Bilim Dalı Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu